The global 27 cancer blockbuster drugs market size is set to surpass US$ 120 billion by 2025.
“Global Oncology/Cancer Blockbuster Drugs Market Research Report 2019 - 2025” presents an in-depth assessment of the global cancer blockbuster drugs market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook for global cancer blockbuster drugs market. The report includes historical data from 2015 to 2018 and forecasts until 2025.
The report contains a granular analysis of the present industry situations, market demands, reveal facts on the market size, revenues and provides forecasts through 2025.The report provides clear insight into current and future developments of the global cancer blockbuster drugs market. The report explores detailed analysis of top 27 drugs market assessment globally from 2015 to 2018 and forecasts to 2025.
Key trends in terms of collaboration, merger & acquisition, partnerships, distribution and licensing agreement are analyzed with details. The report also explores detailed description of growth drivers and inhibitors of the global cancer blockbuster drugs market.
The report concludes with the profiles of major players in the global cancer blockbuster drugs market. The key market players are evaluated on various parameters such as business overview and recent development.
The Major Companies Dominating this Market for its Products, Services and Continuous Product Developments are:
1. Roche
2. Bristol-Myers Squibb
3. Pfizer
4. Eli Lilly and Company
5. Merck
6. Johnson & Johnson
7. AstraZeneca
8. Celgene
9. Novartis
10. Amgen
Top 27 Cancer Blockbuster Drugs Covered Under This Report Are:
1. Imbruvica
2. Revlimid
3. Pomalyst/Imnovid
4. Keytruda
5. Herceptin
6. Avastin
7. MabThera/Rituxan
8. Perjeta
9. Opdivo
10. Sprycel
11. Ibrance
12. Zytiga
13. Tagrisso
14. Darzalex
15. Xtandi
16. Jakafi/Jakavi
17. Yervoy
18. Alimta
19. Gleevec/Glivec
20. Velcade
21. Tasigna
22. Xgeva
23. Afinitor/Votubia
24. Neulasta
25. Exjade Jadenu
26. Sandostatin
27. Faslodex
The Latest Industry Data Included in this Report:
Global Top 27 Cancer Blockbuster Drugs Market Size & Analysis (2015 – 2025)
Global Top 27 Cancer Blockbuster Drugs Market Share & Y–o–Y Growth (%), 2015 – 2025
Global Top 27 Cancer Blockbuster Drugs Market Assessment & Opportunity, (2015 – 2025)
Major Deals (Mergers, Acquisitions, Key Agreements, Partnerships & Collaborations)
Key Market Drivers and Inhibitors of the Global Cancer Blockbuster Drugs Market
Major Companies Analysis
The Report Answers the Following Questions about the Global Cancer Blockbuster Drugs Market:
What is the size of the global top 27 cancer blockbuster drugs market during 2015 -2025?
What will be the revenue generated by each drug during the forecast period?
Which major drugs provides highest market share?
How are the overall market and major drugs growing?
What are the key drivers and inhibitors in the current market?
What will be the impact of drivers and inhibitors in the future?
How is the market predicted to develop in the future?
Who are the key players in this market space?
'
1. Executive Summary
2. Global Top 27 Cancer Blockbuster Drugs Market Size & Analysis (2015 – 2025)
3. Global Top 27 Cancer Blockbuster Drugs Market Share & Y–o–YGrowth (%), 2015 – 2025
4. Key Drivers and Inhibitors of the Global Cancer Blockbuster Drugs Market
4.1 Market Drivers
4.2 Market Inhibitors
5. Global Top 27 Cancer Blockbuster Drugs Market Assessment & Opportunity, (2015 – 2025)
5.1 Imbruvica (Ibrutinib)
5.2 Revlimid (Lenalidomide)
5.3 Pomalyst/Imnovid (Pomalidomide)
5.4 Keytruda (Pembrolizumab)
5.5 Herceptin (Trastuzumab)
5.6 Avastin (Bevacizumab)
5.7 MabThera/Rituxan (Rituximab)
5.8 Perjeta (Pertuzumab)
5.9 Opdivo (Nivolumab)
5.10 Sprycel (Dasatinib)
5.11 Ibrance (Palbociclib)
5.12 Zytiga (Abiraterone acetate)
5.13 Tagrisso (Osimertinib)
5.14 Darzalex (Daratumumab)
5.15 Xtandi (Enzalutamide)
5.16 Jakafi/Jakavi (Ruxolitinib Phosphate)
5.17 Yervoy (Ipilimumab)
5.18 Alimta (Pemetrexed)
5.19 Gleevec/Glivec (Imatinib Mesylate)
5.20 Velcade (Bortezomib)
5.21 Tasigna (Nilotinib)
5.22 Xgeva (Denosumab)
5.23 Afinitor/Votubia (Everolimus)
5.24 Neulasta (Pegfilgrastim)
5.25 Exjade Jadenu (Deferasirox)
5.26 Sandostatin (Octreotide Acetate)
5.27 Faslodex (Fulvestrant)
6. Major Deals in Cancer Drugs Market
6.1 Collaboration Deals
6.2 Merger and Acquisitions
6.3 Licensing Agreement
6.4 Partnership Deals
6.5 Distribution Agreement
7. Key Companies Analysis
7.1 Roche
7.1.1 Business Overview
7.1.2 Recent Development
7.2 Bristol-Myers Squibb
7.2.1 Business Overview
7.2.2 Recent Development
7.3 Pfizer
7.3.1 Business Overview
7.3.2 Recent Development
7.4 Eli Lilly and Company
7.4.1 Business Overview
7.4.2 Recent Development
7.5 Merck
7.5.1 Business Overview
7.5.2 Recent Development
7.6 Johnson & Johnson
7.6.1 Business Overview
7.6.2 Recent Development
7.7 AstraZeneca
7.7.1 Business Overview
7.7.2 Recent Development
7.8 Celgene
7.8.1 Business Overview
7.8.2 Recent Development
7.9 Novartis
7.9.1 Business Overview
7.9.2 Recent Developmnet
7.10 Amgen
7.10.1 Business Overview
7.10.2 Recent Development
List of Tables
Table 3–1: Global Top 27 Cancer Blockbuster Drugs Market Share & Y–o–Y Growth (%), 2015 – 2018
Table 3–2: Global Top 27 Cancer Blockbuster Drugs Market Share & Y–o–Y Growth Forecast (%), 2019 – 2025
Table 7–1: Collaboration Deals in Cancer Drugs Market
Table 7–2: Merger and Acquisitions in Cancer Drugs Market
Table 7–3: Licensing Agreement in Cancer Drugs Market
Table 7–4: Partnership Deals in Cancer Drugs Market
Table 7–5: Distribution Agreement in Cancer Drugs Market
List of Figures
Figure 2–1: Global Top 27 Cancer Blockbuster Drugs Market Size (Million US$),2015 – 2018
Figure 2–2: Global Top 27 Cancer Blockbuster Drugs Market Size Forecast (Million US$),2019 – 2025
Figure 4–1: Global Ageing Population & Forecast (Million), 2010 – 2050
Figure 5–1: Global Imbruvica Market Value (Million US$),2015 – 2018
Figure 5–2: Global Imbruvica Market Value Forecast (Million US$),2019 – 2025
Figure 5–3: Global Revlimid Market Value (Million US$),2015 – 2018
Figure 5–4: Global Revlimid Market Value Forecast (Million US$),2019 – 2025
Figure 5–5: Global Pomalyst/Imnovid Market Value (Million US$),2015 – 2018
Figure 5–6: Global Pomalyst/Imnovid Market Value Forecast (Million US$),2019 – 2025
Figure 5–7: Global Keytruda Market Value (Million US$),2015 – 2018
Figure 5–8: Global Keytruda Market Value Forecast (Million US$),2019 – 2025
Figure 5–9: Global Herceptin Market Value (Million US$),2015 – 2018
Figure 5–10: Global Herceptin Market Value Forecast (Million US$),2019 – 2025
Figure 5–11: Global Avastin Market Value (Million US$),2015 – 2018
Figure 5–12: Global Avastin Market Value Forecast (Million US$),2019 – 2025
Figure 5–13: Global MabThera/Rituxan Market Value (Million US$),2015 – 2018
Figure 5–14: Global MabThera/Rituxan Market Value Forecast (Million US$),2019 – 2025
Figure 5–15: Global Perjeta Market Value (Million US$),2015 – 2018
Figure 5–16: Global Perjeta Market Value Forecast (Million US$),2019 – 2025
Figure 5–17: Global Opdivo Market Value (Million US$),2015 – 2018
Figure 5–18: Global Opdivo Market Value Forecast (Million US$),2019 – 2025
Figure 5–19: Global Sprycel Market Value (Million US$),2015 – 2018
Figure 5–20: Global Sprycel Market Value Forecast (Million US$),2019 – 2025
Figure 5–21: Global Ibrance Market Value (Million US$),2015 – 2018
Figure 5–22: Global Ibrance Market Value Forecast (Million US$),2019 – 2025
Figure 5–23: Global Zytiga Market Value (Million US$),2015 – 2018
Figure 5–24: Global Zytiga Market Value Forecast (Million US$),2019 – 2025
Figure 5–25: Global Tagrisso Market Value (Million US$),2015 – 2018
Figure 5–26: Global Tagrisso Market Value Forecast (Million US$),2019 – 2025
Figure 5–27: Global Darzalex Market Value (Million US$),2015 – 2018
Figure 5–28: Global Darzalex Market Value Forecast (Million US$),2019 – 2025
Figure 5–29: Global Xtandi Market Value (Million US$),2015 – 2018
Figure 5–30: Global Xtandi Market Value Forecast (Million US$),2019 – 2025
Figure 5–31: Global Jakafi/Jakavi Market Value (Million US$),2015 – 2018
Figure 5–32: Global Jakafi/Jakavi Market Value Forecast (Million US$),2019 – 2025
Figure 5–33: Global Yervoy Market Value (Million US$),2015 – 2018
Figure 5–34: Global Yervoy Market Value Forecast (Million US$),2019 – 2025
Figure 5–35: Global Alimta Market Value (Million US$),2015 – 2018
Figure 5–36: Global Alimta Market Value Forecast (Million US$),2019 – 2025
Figure 5–37: Global Gleevec/Glivec Market Value (Million US$),2015 – 2018
Figure 5–38: Global Gleevec/Glivec Market Value Forecast (Million US$),2019 – 2025
Figure 5–39: Global Velcade Market Value (Million US$),2015 – 2018
Figure 5–40: Global Velcade Market Value Forecast (Million US$),2019 – 2025
Figure 5–41: Global Tasigna Market Value (Million US$),2015 – 2018
Figure 5–42: Global Tasigna Market Value Forecast (Million US$),2019 – 2025
Figure 5–43: Global Xgeva Market Value (Million US$),2015 – 2018
Figure 5–44: Global Xgeva Market Value Forecast (Million US$),2019 – 2025
Figure 5–45: Global Afinitor/Votubia Market Value (Million US$),2015 – 2018
Figure 5–46: Global Afinitor/Votubia Market Value Forecast (Million US$),2019 – 2025
Figure 5–47: Global Neulasta Market Value (Million US$),2015 – 2018
Figure 5–48: Global Neulasta Market Value Forecast (Million US$),2019 – 2025
Figure 5–49: Global Exjade Jadenu Market Value (Million US$),2015 – 2018
Figure 5–50: Global Exjade Jadenu Market Value Forecast (Million US$),2019 – 2025
Figure 5–51: Global Sandostatin Market Value (Million US$),2015 – 2018
Figure 5–52: Global Sandostatin Market Value Forecast (Million US$),2019 – 2025
Figure 5–53: Global Faslodex Market Value (Million US$),2015 – 2018
Figure 5–54: Global Faslodex Market Value Forecast (Million US$),2019 – 2025
